Halozyme Therapeutics (HALO) Tops Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $81.57 --0%
Revenue Growth %: +23.1%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +23.1%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $39 million versus the consensus estimate of $38.37 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Palladyne AI reports preliminary Q2 revenue of ~$5.8M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
